Evidence map›Paper›PMID 36248318›Full record

ArticleCritical care explorations2022

Outcomes of Extracorporeal Membrane Oxygenation in COVID-19-Induced Acute Respiratory Distress Syndrome: An Inverse Probability Weighted Analysis.

Senta Jorinde Raasveld, Fabio Silvio Taccone, Lars Mikael Broman, Greet Hermans, Philippe Meersseman, Manuel Quintana Diaz, Thijs S R Delnoij, Marcel van de Poll, Elisa Gouvea Bogossian, Floor L F van Baarle and 15 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Critical care explorations, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
0.6field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 11 institutions in 5 countries.

Senta Jorinde RaasveldDepartment of Critical Care, Amsterdam University Medical Centers, Location Academic Medical Centers, Amsterdam, The Netherlands.
Fabio Silvio TacconeDepartment of Intensive Care, Université Libre de Bruxelles, Hôpital Erasme Bruxelles, Brussels, Belgium.
Lars Mikael BromanDepartment of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
Greet HermansMedical Intensive Care Unit, Department of General Internal Medicine, University Hospitals Leuven, Leuven, Belgium.
Philippe MeerssemanMedical Intensive Care Unit, Department of General Internal Medicine, University Hospitals Leuven, Leuven, Belgium.
Manuel Quintana DiazDepartment of Intensive Care, Hospital Universitario La Paz, Madrid, Spain.
Thijs S R DelnoijDepartment of Cardiology, Maastricht University Medical Center, Maastricht, The Netherlands.
Marcel van de PollDepartment of Intensive Care, Maastricht University Medical Center, Maastricht, the Netherlands.
Elisa Gouvea BogossianDepartment of Intensive Care, Université Libre de Bruxelles, Hôpital Erasme Bruxelles, Brussels, Belgium.
Floor L F van BaarleDepartment of Critical Care, Amsterdam University Medical Centers, Location Academic Medical Centers, Amsterdam, The Netherlands.
Koray DurakDepartment of Thoracic and Cardiovascular Surgery, RWTH University Hospital Aachen, Aachen, Germany.
Rashad ZayatDepartment of Thoracic and Cardiovascular Surgery, RWTH University Hospital Aachen, Aachen, Germany.
Annemieke Oude Lansink-HartgringDepartment of Critical Care, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Christiaan L MeuweseDepartment of Intensive Care Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands.
Joris J van der HeijdenIntensive Care Centre, University Medical Center Utrecht (UMCU), Utrecht, The Netherlands.
Erwin de TroyDepartment of Intensive Care Medicine, Surgical Intensive Care Unit, University Hospitals Leuven, Leuven, Belgium.
Dieter DauweDepartment of Intensive Care Medicine, Surgical Intensive Care Unit, University Hospitals Leuven, Leuven, Belgium.
Erik ScholtenDepartment of Intensive Care, St. Antonius Hospital, Nieuwegein, The Netherlands.
Franciska van der VeldeDepartment of Intensive Care Medicine, Leiden University Medical Center, Leiden, The Netherlands.
Jacinta J MaasDepartment of Intensive Care Medicine, Leiden University Medical Center, Leiden, The Netherlands.
Dinis Dos Reis MirandaDepartment of Intensive Care Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands.
Marijn KuijpersDepartment of Intensive Care Medicine, Isala Hospital, Zwolle, The Netherlands.
Judith van den BruleDepartment of Intensive Care Medicine, Radboud Hospital, Nijmegen, Tthe Netherlands.
Walter M van den BerghDepartment of Critical Care, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Alexander P J VlaarDepartment of Critical Care, Amsterdam University Medical Centers, Location Academic Medical Centers, Amsterdam, The Netherlands.
KU Leuven · BEMaastricht University · NLErasmus MC · NLKarolinska Institutet · SERWTH Aachen University · DEUniversity of Groningen · NLErasmus Hospital · BEHospital Universitario La Paz · ESIsala · NLLeiden University Medical Center · NLUniversité Libre de Bruxelles · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although venovenous extracorporeal membrane oxygenation (VV ECMO) has been used in case of COVID-19 induced acute respiratory distress syndrome (ARDS), outcomes and criteria for its application should be evaluated.

objectivesTo describe patient characteristics and outcomes in patients receiving VV ECMO due to COVID-19-induced ARDS and to assess the possible impact of COVID-19 on mortality. DESIGN SETTING AND

participantsMulticenter retrospective study in 15 ICUs worldwide. All adult patients (> 18 yr) were included if they received VV ECMO with ARDS as main indication. Two groups were created: a COVID-19 cohort from March 2020 to December 2020 and a "control" non-COVID ARDS cohort from January 2018 to July 2019. MAIN OUTCOMES AND MEASURES: Collected data consisted of patient demographics, baseline variables, ECMO characteristics, and patient outcomes. The primary outcome was 60-day mortality. Secondary outcomes included patient characteristics, COVID-19-related therapies before and during ECMO and complication rate. To assess the influence of COVID-19 on mortality, inverse probability weighted (IPW) analyses were used to correct for predefined confounding variables.

resultsA total of 193 patients with COVID-19 received VV ECMO. The main indication for VV ECMO consisted of refractory hypoxemia, either isolated or combined with refractory hypercapnia. Complications with the highest occurrence rate included hemorrhage, an additional infectious event or acute kidney injury. Mortality was 35% and 45% at 28 and 60 days, respectively. Those mortality rates did not differ between the first and second waves of COVID-19 in 2020. Furthermore, 60-day mortality was equal between patients with COVID-19 and non-COVID-19-associated ARDS receiving VV ECMO (hazard ratio 60-d mortality, 1.27; 95% CI, 0.82-1.98; CONCLUSIONS AND RELEVANCE: Mortality for patients with COVID-19 who received VV ECMO was similar to that reported in other COVID-19 cohorts, although no differences were found between the first and second waves regarding mortality. In addition, after IPW, mortality was independent of the etiology of ARDS.

Indexed as

acute respiratory distress syndromeCOVID-19extracorporeal membrane oxygenationmortalityvenovenous extracorporeal membrane oxygenation

Identifiers

PMID36248318
PMCPMC9553386
OpenAlexW4304140863

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.